Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) slipped $2.25 to $152.87 last week after FDA granted full approval to Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS). The agency granted accelerated approval for Soliris for the indication in 2011. Soliris already has full approval in the U.S. to treat paroxysmal nocturnal hemoglobinuria (PNH).
Biota Pharmaceuticals Inc. (NASDAQ:BOTA) lost $0.58 (16%) to $3.01 last week after saying HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA) terminated a 2011 contract worth up to $231 million to develop laninamivir octanoate. Biota said HHS did not provide a reason for the termination. Biota's stock has fallen 46% since April 28, before receiving a stop-work order for the influenza product.